Gynecologic Oncology | Specialty

The gynecologic oncology condition center is a comprehensive resource for clinical news and expert insights on gynecologic oncology. Read more at OncLive.

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

February 21st 2025

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.

Dr Pothuri on the Current Treatment Paradigm in Endometrial Cancer

February 14th 2025

Bhavana Pothuri, MD, discusses the current treatment paradigm in endometrial cancer and the targeted therapies currently being investigated.

Dr Wagar on the Role of Adjuvant Immunotherapy in Endometrial Cancer

February 13th 2025

Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.

2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward

February 13th 2025

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field

February 12th 2025

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

Short-Course Radiation Therapy Effective for Endometrial Cancer Patients

February 12th 2025

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

Pembrolizumab Provides Clinical Benefit in Previously Treated Advanced Clear Cell Gynecologic Cancer

February 9th 2025

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer

February 5th 2025

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

February 5th 2025

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology

February 1st 2025

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.

Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer

February 1st 2025

A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.

Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers

January 31st 2025

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.

High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma

January 31st 2025

High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

January 31st 2025

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

January 31st 2025

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

January 30th 2025

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

January 30th 2025

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer

January 27th 2025

Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer

January 20th 2025

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.